Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas Turner

Showing results (101-110 of 138) with videos related to

Pageof 14
Sort By:
Synthetic Biology (Oxford, England)|November 16, 2020
Engineering <i>Escherichia coli</i> towards <i>de novo</i> production of gatekeeper (2<i>S</i>)-flavanones: naringenin, pinocembrin, eriodictyol and homoeriodictyolMark S Dunstan, Christopher J Robinson, Adrian J Jervis, et al.
Breast Cancer Research and Treatment|December 3, 2021
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trialNicholas Turner, Rebecca A Dent, Joyce O'Shaughnessy, et al.
Current Biology : CB|May 26, 2023
Cyclic structure with cellular precision in a vertebrate sensorimotor neural circuitRunzhe Yang, Ashwin Vishwanathan, Jingpeng Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III TrialRebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, et al.
Chemical Communications (Cambridge, England)|May 12, 2020
Chemoenzymatic synthesis of 3-deoxy-3-fluoro-l-fucose and its enzymatic incorporation into glycoconjugatesPablo Valverde, Jean-Baptiste Vendeville, Kristian Hollingsworth, et al.
Nature Neuroscience|November 23, 2024
Predicting modular functions and neural coding of behavior from a synaptic wiring diagramAshwin Vishwanathan, Alex Sood, Jingpeng Wu, et al.
Breast Cancer Research and Treatment|May 14, 2024
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective studyMatilde Corianò, Chiara Tommasi, Anh Thi Lan Dinh, et al.
Science Advances|May 7, 2025
EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasisSheera R Rosenbaum, Connor J Hughes, Kaiah M Fields, et al.
The Lancet. Oncology|March 7, 2021
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trialEric P Winer, Oleg Lipatov, Seock-Ah Im, et al.
The Lancet. Oncology|April 1, 2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
Pageof 14

Showing results (101-110 of 138) with videos related to

Sort By:
Pageof 14
Synthetic Biology (Oxford, England)|November 16, 2020
Engineering <i>Escherichia coli</i> towards <i>de novo</i> production of gatekeeper (2<i>S</i>)-flavanones: naringenin, pinocembrin, eriodictyol and homoeriodictyolMark S Dunstan, Christopher J Robinson, Adrian J Jervis, et al.
Breast Cancer Research and Treatment|December 3, 2021
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trialNicholas Turner, Rebecca A Dent, Joyce O'Shaughnessy, et al.
Current Biology : CB|May 26, 2023
Cyclic structure with cellular precision in a vertebrate sensorimotor neural circuitRunzhe Yang, Ashwin Vishwanathan, Jingpeng Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2024
Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III TrialRebecca A Dent, Sung-Bae Kim, Mafalda Oliveira, et al.
Chemical Communications (Cambridge, England)|May 12, 2020
Chemoenzymatic synthesis of 3-deoxy-3-fluoro-l-fucose and its enzymatic incorporation into glycoconjugatesPablo Valverde, Jean-Baptiste Vendeville, Kristian Hollingsworth, et al.
Nature Neuroscience|November 23, 2024
Predicting modular functions and neural coding of behavior from a synaptic wiring diagramAshwin Vishwanathan, Alex Sood, Jingpeng Wu, et al.
Breast Cancer Research and Treatment|May 14, 2024
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective studyMatilde Corianò, Chiara Tommasi, Anh Thi Lan Dinh, et al.
Science Advances|May 7, 2025
EYA3 regulation of NF-κB and CCL2 suppresses cytotoxic NK cells in the premetastatic niche to promote TNBC metastasisSheera R Rosenbaum, Connor J Hughes, Kaiah M Fields, et al.
The Lancet. Oncology|March 7, 2021
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trialEric P Winer, Oleg Lipatov, Seock-Ah Im, et al.
The Lancet. Oncology|April 1, 2021
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative studyHope S Rugo, Florence Lerebours, Eva Ciruelos, et al.
Pageof 14